Helus Pharma (formerly Cybin) (HELP) — Helus Pharma (the rebranded Cybin) said Michael Cola stepped down as CEO, effective immediately, at the board's request, with co-founder and Executive Chairman Eric So resuming the interim CEO role while a search proceeds.
The leadership change came as the company advances its late-stage psychedelic pipeline, including an anticipated Q4 topline readout from the APPROACH Phase 3 trial of HLP003 (formerly CYB003) in depression. The abrupt transition injected management uncertainty at a pivotal moment for the company.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.